Fibroblast growth factor receptor fusions in cancer: opportunities and challenges

Abstract Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric FGFR fusion proteins, which often cause aberrant signaling leading to the develop...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lingfeng Chen, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li, Guang Liang
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Fibroblast growth factor receptors Fusion proteins Chromosomal translocation Cancer Inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/63d4b06e8e2b4f1aa64ee4415063ed6c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63d4b06e8e2b4f1aa64ee4415063ed6c
record_format	dspace
spelling	oai:doaj.org-article:63d4b06e8e2b4f1aa64ee4415063ed6c2021-11-08T10:44:42ZFibroblast growth factor receptor fusions in cancer: opportunities and challenges10.1186/s13046-021-02156-61756-9966https://doaj.org/article/63d4b06e8e2b4f1aa64ee4415063ed6c2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13046-021-02156-6https://doaj.org/toc/1756-9966Abstract Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric FGFR fusion proteins, which often cause aberrant signaling leading to the development and progression of human cancer. Due to the high recurrence rate and carcinogenicity, oncogenic FGFR gene fusions have been identified as promising therapeutic targets. Erdafitinib and pemigatinib, two FGFR selective inhibitors targeting FGFR fusions, have been approved by the U.S. Food and Drug Administration (FDA) to treat patients with urothelial cancer and cholangiocarcinoma, respectively. Futibatinib, a third-generation FGFR inhibitor, is under phase III clinical trials in patients with FGFR gene rearrangements. Herein, we review the current understanding of the FGF/FGFRs system and the oncogenic effect of FGFR fusions, summarize promising inhibitors under clinical development for patients with FGFR fusions, and highlight the challenges in this field.Lingfeng ChenYanmei ZhangLina YinBinhao CaiPing HuangXiaokun LiGuang LiangBMCarticleFibroblast growth factor receptorsFusion proteinsChromosomal translocationCancerInhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Fibroblast growth factor receptors Fusion proteins Chromosomal translocation Cancer Inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Fibroblast growth factor receptors Fusion proteins Chromosomal translocation Cancer Inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lingfeng Chen Yanmei Zhang Lina Yin Binhao Cai Ping Huang Xiaokun Li Guang Liang Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
description	Abstract Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric FGFR fusion proteins, which often cause aberrant signaling leading to the development and progression of human cancer. Due to the high recurrence rate and carcinogenicity, oncogenic FGFR gene fusions have been identified as promising therapeutic targets. Erdafitinib and pemigatinib, two FGFR selective inhibitors targeting FGFR fusions, have been approved by the U.S. Food and Drug Administration (FDA) to treat patients with urothelial cancer and cholangiocarcinoma, respectively. Futibatinib, a third-generation FGFR inhibitor, is under phase III clinical trials in patients with FGFR gene rearrangements. Herein, we review the current understanding of the FGF/FGFRs system and the oncogenic effect of FGFR fusions, summarize promising inhibitors under clinical development for patients with FGFR fusions, and highlight the challenges in this field.
format	article
author	Lingfeng Chen Yanmei Zhang Lina Yin Binhao Cai Ping Huang Xiaokun Li Guang Liang
author_facet	Lingfeng Chen Yanmei Zhang Lina Yin Binhao Cai Ping Huang Xiaokun Li Guang Liang
author_sort	Lingfeng Chen
title	Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
title_short	Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
title_full	Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
title_fullStr	Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
title_full_unstemmed	Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
title_sort	fibroblast growth factor receptor fusions in cancer: opportunities and challenges
publisher	BMC
publishDate	2021
url	https://doaj.org/article/63d4b06e8e2b4f1aa64ee4415063ed6c
work_keys_str_mv	AT lingfengchen fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges AT yanmeizhang fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges AT linayin fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges AT binhaocai fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges AT pinghuang fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges AT xiaokunli fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges AT guangliang fibroblastgrowthfactorreceptorfusionsincanceropportunitiesandchallenges
_version_	1718442621613899776

Fibroblast growth factor receptor fusions in cancer: opportunities and challenges

Ejemplares similares